Bishal Gyawali: The case of cancer drug Xtandi
Bishal Gyawali, Associate Professor at Queen’s University, Kingston, Canada, posted on LinkedIn about recent paper by him as first author, titled “Government Funding for the Development of Enzalutamide” published on JAMA Oncology.
Authors: Bishal Gyawali, Emily H. Jung, Helen Mooney, Jerry Avorn, Aaron S. Kesselheim
“In this new paper published today in JAMA Oncology, we discuss the case of cancer drug Xtandi whose early stage developments were heavily funded by government grants and public funds but now is priced more in the U.S. than in other high-income countries. Several lessons for cancer policy.”
Bishal Gyawali, MD, PhD, is a medical oncologist from Nepal. Currently an Associate Professor at Queen’s University, Kingston, Canada, and affiliated with Brigham and Women’s Hospital, Boston, USA, he is involved in global oncology initiatives. Dr. Gyawali serves on several committees, including the WHO Essential Medicines List Cancer Medicines Working Group and ASCO’s Health Equity and Outcomes Committee, contributing significantly to cancer policy and evidence-based oncology.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023